Direkt zum Inhalt
Merck

Postprandial hyperglycaemia and vascular damage--the benefits of acarbose.

Diabetes & vascular disease research (2006-10-25)
Peter N Båvenholm, Suad Efendic
ZUSAMMENFASSUNG

Traditional risk factors do not fully explain the increased risk of cardiovascular disease (CVD) in diabetes. Epidemiology shows that hyperglycaemia is a continuous CVD risk factor and that two-hour postprandial glucose levels are more strongly associated with CVD than fasting glucose. Good glycaemic control is proven to reduce the risk of microvascular complications, but equivalent evidence for CVD risk reduction is lacking. However, in the Study to Prevent Non-Insulin Dependent Diabetes Mellitus (STOP-NIDDM), acarbose reduced the risk of diabetes in those with impaired glucose tolerance by 36% (p=0.0017) and the risk of any cardiovascular event by 49% (p=0.0326) versus placebo. Furthermore, a meta-analysis of trials of acarbose in patients with type 2 diabetes suggests a significant reduction of CVD events. This review examines evidence that postprandial hyperglycaemia plays a major role in vascular damage, particularly through non-traditional risk factors such as oxidative stress and subclinical inflammation, and how acarbose may prevent this damage.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Acarbose, ≥95% (HPLC)
Supelco
Acarbose, Pharmaceutical Secondary Standard; Certified Reference Material
Acarbose, European Pharmacopoeia (EP) Reference Standard
Acarbose für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard
Acarbose für die Identifizierung, European Pharmacopoeia (EP) Reference Standard